Alpha-Synuclein Neurobiology in Parkinson’s Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives
Open Access
- 25 November 2025
- journal article
- review article
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1260
Abstract
Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN) and the presence of intracellular α-synuclein (αSyn) aggregates known as Lewy bodies (LB). αSyn, a presynaptic protein, is believed to play a crucial role in synaptic function, neurotransmitter release, and neuronal plasticity. However, its misfolding and aggregation are thought to be central to PD pathogenesis. This review provides a comprehensive analysis of αSyn’s role in PD, exploring its normal physiological functions, pathological mechanisms, and therapeutic potential. The pathological transformation of αSyn involves structural alterations that promote oligomerization and fibrillization, leading to toxic gain-of-function effects. These aggregates disrupt cellular homeostasis through mechanisms including mitochondrial dysfunction, oxidative stress, lysosomal impairment, and endoplasmic reticulum stress. Furthermore, pathogenic αSyn is thought to exacerbate neurodegeneration via prion-like spread along interconnected neuronal circuits. Emerging evidence highlights the frequent co-occurrence of other proteinopathies, such as tau and amyloid-β, which may synergistically accelerate disease progression. Targeting αSyn has emerged as a potential therapeutic strategy. Approaches such as immunotherapy, small-molecule inhibitors, gene silencing, and modulation of protein degradation pathways (e.g., autophagy and proteasomal systems) are actively being explored. Additionally, lifestyle-based interventions, particularly exercise, have shown neuroprotective effects, potentially mediated by irisin—a myokine implicated in protein clearance and synaptic resilience—underscoring the importance of multimodal strategies in PD management.Keywords
This publication has 245 references indexed in Scilit:
- Blood α‐Synuclein Separates Parkinson's Disease from Dementia with Lewy BodiesAnnals of Neurology, 2025
- Modeling Parkinson's disease‐related symptoms in alpha‐synuclein overexpressing miceBrain and Behavior, 2022
- Lewy Body–like Inclusions in Human Midbrain Organoids Carrying Glucocerebrosidase and α‐Synuclein MutationsAnnals of Neurology, 2021
- A novel tau‐based rhesus monkey model of Alzheimer's pathogenesisAlzheimer's & Dementia, 2021
- Identification of Risk Loci for Parkinson Disease in Asians and Comparison of Risk Between Asians and EuropeansJAMA Neurology, 2020
- Early fine motor impairment and behavioral dysfunction in (Thy‐1)‐h[A30P] alpha‐synuclein miceBrain and Behavior, 2018
- G51D α‐synuclein mutation causes a novel Parkinsonian–pyramidal syndromeAnnals of Neurology, 2013
- Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson DiseaseJAMA, 2006
- α‐Synuclein pathology does not predict extrapyramidal symptoms or dementiaAnnals of Neurology, 2004
- Comparison of kindreds with parkinsonism and α‐synuclein genomic multiplicationsAnnals of Neurology, 2004